A biotechnology sector-specific exchange traded fund specialized in tracking immunotherapy drugmakers bucked the broader market trends and surged Wednesday after MacroGenics (NasdaqGS: MGNX) announced upbeat breast cancer trial results.

The Loncar Cancer Immunotheraphy ETF (NasdaqGM: CNCR), which tracks companies that are developing new classes of therapies, increased 4.3% on Wednesday.

Fueling the gains in CNCR, MacroGenics shares jumped 126.5% on over 41 times its average daily volume. MGNX makes up 3.0% of CNCR’s underlying portfolio.

The cancer specalist MacroGenics popped off early Wednesday morning in response to a positive late-stage result for its HER2-positive breast cancer treatment candidate, margetuximab, The Motley Fool reported.

According to the press release, patients treated with a combination of margetuximab and chemotherapy demonstrated a statistically significant improvement in progression-free survival (PFS) compared to those receiving Roche’s Herceptin plus chemotherapy.

Subscribe to our free daily newsletters!
Please enter your email address to subscribe to ETF Trends' newsletters featuring latest news and educational events.